Literature DB >> 25846095

Correction to Lancet Oncol 2014; 15: 856. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

J Ledermann, P Harter, C Gourley.   

Abstract

Entities:  

Year:  2015        PMID： 25846095     DOI： 10.1016/S1470-2045(15)70153-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  5 in total

1.  Blueberries inhibit cyclooxygenase-1 and cyclooxygenase-2 activity in human epithelial ovarian cancer.

Authors:  Wumei Lin; Zhigang Li
Journal:  Oncol Lett       Date:  2017-04-25       Impact factor: 2.967

2.  Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.

Authors:  Hemant Malhotra; Pradnya Kowtal; Nikita Mehra; Raja Pramank; Rajiv Sarin; Thangarajan Rajkumar; Sudeep Gupta; Ajay Bapna; Gouri Shankar Bhattacharyya; Sabhyata Gupta; Amita Maheshwari; Ashraf U Mannan; Ravindra Reddy Kundur; Rupinder Sekhon; Manish Singhal; B K Smruti; Somashekhar Sp; Moushumi Suryavanshi; Amit Verma
Journal:  JCO Glob Oncol       Date:  2020-07

3.  A PARP1-related prognostic signature constructing and PARP-1 inhibitors screening for glioma.

Authors:  Hui Li; Zhenhua Wang; Yuanyuan Hou; Jianxin Xi; Zhenqiang He; Han Lu; Zhishan Du; Sheng Zhong; Qunying Yang
Journal:  Front Cell Dev Biol       Date:  2022-08-24

Review 4.  An update on clinical oncology for the non-oncologist.

Authors:  Rafael Aliosha Kaliks
Journal:  Einstein (Sao Paulo)       Date:  2016 Apr-Jun

5.  The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.

Authors:  Pi-Lin Sung; Kuo-Chang Wen; Yi-Jen Chen; Ta-Chung Chao; Yi-Fang Tsai; Ling-Ming Tseng; Jian-Tai Timothy Qiu; Kuan-Chong Chao; Hua-Hsi Wu; Chi-Mu Chuang; Peng-Hui Wang; Chi-Ying F Huang
Journal:  PLoS One       Date:  2017-09-29       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.